Revolution Healthcare Acquisition Corp. SAIL Units
REVHU
REVHU was delisted on the 5th of December, 2022.
0 hedge funds and large institutions have $0 invested in Revolution Healthcare Acquisition Corp. SAIL Units in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 21 closing their positions.
100% less funds holding
Funds holding: 21 → 0 (-21)
100% less capital invested
Capital invested by funds: $73.4M → $0 (-$73.4M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 21
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$44.1M |
| 2 |
Jane Street
New York
|
-$11.3M |
| 3 |
DPCM
Darlington Partners Capital Management
Greenbrae,
California
|
-$9.57M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$4.91M |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$1.14M |
REVHU Hedge Fund Activity: Q4 2022 in Review
0 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Revolution Healthcare Acquisition Corp. SAIL Units (REVHU) for Q4 2022, worth a combined $0 — down 100% from $73.4M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of REVHU and 0 opened new positions — a net loss of 21 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $44.1M sold.
- 0 institutional investors held Revolution Healthcare Acquisition Corp. SAIL Units (REVHU) as of Q4 2022, down from 21 in Q3 2022.
- Funds reported $0 of Revolution Healthcare Acquisition Corp. SAIL Units stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new Revolution Healthcare Acquisition Corp. SAIL Units positions in Q4 2022 and 21 closed out, a net change of -21 holders.
- The largest Revolution Healthcare Acquisition Corp. SAIL Units seller in Q4 2022 was T. Rowe Price Associates, an estimated $44.1M sold.
Based on aggregated 13F filings for Q4 2022.